4311/B Ciba
Brand names,
4311/B Ciba
Analogs
4311/B Ciba
Brand Names Mixture
4311/B Ciba
Chemical_Formula
C14H19NO2
4311/B Ciba
RX_link
http://www.rxlist.com/cgi/generic/methphen.htm
4311/B Ciba
fda sheet
4311/B Ciba
msds (material safety sheet)
4311/B Ciba
Synthesis Reference
M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)
4311/B Ciba
Molecular Weight
233.306 g/mol
4311/B Ciba
Melting Point
224-226oC
4311/B Ciba
H2O Solubility
1255mg/L
4311/B Ciba
State
Solid
4311/B Ciba
LogP
3.192
4311/B Ciba
Dosage Forms
Tablets; Tablets (sustained release)
4311/B Ciba
Indication
For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.
4311/B Ciba
Pharmacology
Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.
4311/B Ciba
Absorption
Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)
4311/B Ciba
side effects and Toxicity
Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)
4311/B Ciba
Patient Information
4311/B Ciba
Organisms Affected
Humans and other mammals